GLTO
Galecto, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.58
−3.36%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+22.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Feb 12, 2026 | Bruno Julianne · director | M-Exempt | 129,000 | $0.00 |
| Feb 12, 2026 | Bruno Julianne · director | M-Exempt | 129 | $0.00 |
| Feb 12, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | M-Exempt | 5,809,000 | $0.00 |
| Feb 12, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | M-Exempt | 2,904,000 | $0.00 |
| Feb 12, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | M-Exempt | 5,809 | $0.00 |
| Feb 12, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | M-Exempt | 2,904 | $0.00 |
| Jan 26, 2026 | Sattarzadeh Sherwin · officer: Chief Operating Officer | A-Award | 444,209 | $22 |
| Jan 26, 2026 | Sattarzadeh Sherwin · officer: Chief Operating Officer | A-Award | 190,376 | $0.00 |
| Jan 7, 2026 | Hewes L. Becker · officer: Chief Medical Officer | A-Award | 528,603 | $22 |
| Jan 7, 2026 | Hewes L. Becker · officer: Chief Medical Officer | A-Award | 264,629 | $0.00 |
| Jan 6, 2026 | Schambye Hans T. · director, officer: Chief Executive Officer | M-Exempt | 1,360 | $0.00 |
| Jan 6, 2026 | Schambye Hans T. · director, officer: Chief Executive Officer | Sale | 700 | $21 |
| Jan 6, 2026 | Winslow Garrett · officer: General Counsel | M-Exempt | 680 | $0.00 |
| Jan 6, 2026 | Winslow Garrett · officer: General Counsel | Sale | 255 | $21 |
| Jan 6, 2026 | Firmani Lori · officer: Chief Financial Officer | M-Exempt | 374 | $0.00 |
| Jan 6, 2026 | Firmani Lori · officer: Chief Financial Officer | Sale | 135 | $21 |
| Jul 8, 2025 | Schambye Hans T. · director, officer: Chief Executive Officer | M-Exempt | 1,360 | $0.00 |
| Jul 8, 2025 | Schambye Hans T. · director, officer: Chief Executive Officer | Sale | 735 | $3.38 |
| Jul 8, 2025 | Winslow Garrett · officer: General Counsel | M-Exempt | 680 | $0.00 |
| Jul 8, 2025 | Winslow Garrett · officer: General Counsel | Sale | 260 | $3.39 |
| Jul 8, 2025 | Firmani Lori · officer: Interim CFO | M-Exempt | 374 | $0.00 |
| Jul 8, 2025 | Firmani Lori · officer: Interim CFO | Sale | 147 | $3.39 |
| Jun 20, 2025 | Dallas Jayson Donald Alexander · director | A-Award | 720 | $3.22 |
| Jun 20, 2025 | Munshi Amit · director | A-Award | 720 | $3.22 |
| Jun 20, 2025 | Shapiro David · director | A-Award | 720 | $3.22 |
| Jun 20, 2025 | Prener Anne · director | A-Award | 720 | $3.22 |
| Jun 20, 2025 | WECHSLER AMY B · director | A-Award | 720 | $3.22 |
| Jun 20, 2025 | GOLDFISCHER CARL · director | A-Award | 1,440 | $3.22 |
| Jan 7, 2025 | Winslow Garrett · officer: General Counsel | A-Award | 6,000 | $5.70 |
| Jan 7, 2025 | Winslow Garrett · officer: General Counsel | M-Exempt | 1,320 | $0.00 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Feb 12, 2026